---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pharmacodynamics"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Pharmacodynamics. Topics: Bradykinin challenge in healthy volunteers: design, Bradykinin challenge in healthy volunteers: composite EC50 and EC85, Bradykinin challenge in healthy volunteers: duration of effect compared with icatibant, Bradykinin challenge in non-human primates, and 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Bradykinin challenge in healthy volunteers: design

> “PHA-022121 (12 and 22 mg) was administered orally (p.o.) to 16 healthy volunteers.”
> “Bradykinin injections were administered to induce cardiovascular responses.”
> “PHA-022121-induced changes of these BK responses were evaluated with a nonlinear mixed-effect PK/PD model. The results were compared to published results obtained from icatibant (3).”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-2.1.2.6.2-2"></a>

### Bradykinin challenge in healthy volunteers: composite EC50 and EC85

> “PK/PD analysis showed significant inhibition of bradykinin-induced cardiovascular changes with an average composite EC50 of 2.4 and EC85 of 13.8 ng/mL.”
> “Fifteen minutes after a 12-mg dose in fasting conditions, plasma levels reached 60.3 ng/mL, largely above these therapeutic thresholds.”
> “The in vivo PHA-022121 EC50 value of 2.4 ng/mL corresponds to a potency of 170 pM (free plasma concentration)”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

> “Deucrictibant ~4x higher potent vs.”
> “icatibant (published data1)”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-3"></a>

### Bradykinin challenge in healthy volunteers: duration of effect compared with icatibant

> “The investigated single oral doses of PHA-022121 (12 and 22 mg) provide equivalent BK-antagonism for a longer time than a 30 mg s.c. icatibant injection.”
> “The table shows that using the same criteria the durations of effect for the investigated doses of PHA-022121 exceed that of 30 mg icatibant s.c. and are approximately twice as long for the higher dose (equivalent to two icatibant injections 6 h apart).”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

> “PK/PD analysis indicates that effective bradykinin inhibiting concentrations can be reached within 15 min and maintained for at least 12 h, which makes it well suited for development as a single oral dose treatment of acute HAE attacks.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="topic-2.1.2.6.2-4"></a>

### Bradykinin challenge in non-human primates

> “In non-human primates, oral deucrictibant inhibited bradykinin effects with rapid achievement of maximal activity”
> “Deucrictibant / bradykinin challenge”
> “Maximal activity at 1 hour”
> “Icatibant / bradykinin challenge”
> “Maximal activity at 2 hours”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-5"></a>

### EC85 as a surrogate threshold for onset and duration of clinical effect

> “For bradykinin B2 receptor antagonism (icatibant), concentrations predicted to be above EC85 were shown to correlate with therapeutic efficacy and its duration”
> “Achievement and persistence of plasma concentrations ≥EC85 are considered to be therapeutically relevant for deucrictibant as surrogate markers of its onset and duration of clinical effects, respectively”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-6"></a>

### Bradykinin challenge as the basis for dose selection and its consistency with phase 2 results

> “The bradykinin challenge was validated as a surrogate assessment for dose selection in the original development program for icatibant, as reviewed by the FDA and the EMA. From the bradykinin challenge model, we were able to predict the efficacious dose range and the duration of effect of a single oral dose of deucrictibant; the topline data from our Phase 2 RAPIDe-1 trial treating HAE attacks were consistent with the predictions of the bradykinin challenge in both onset of symptom relief and duration of effect (use of rescue medication).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.2-7"></a>

### Onset of clinical effect relative to therapeutic exposure in RAPIDe-3

> “The rapid achievement of end of progression in under 18 min is consistent with the pharmacokinetics of deucrictibant immediate-release capsule, exceeding the threshold concentration for therapeutic exposure (EC85) within 15 min, as previously shown in adults and confirmed in adolescents in this trial.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
